Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Neoadjuvant REGN2810 (Cemiplimab) or REGN2810 (Cemiplimab) Plus REGN3767 (Fianlimab) in Cutaneous Basal Cell Carcinoma of the Head and Neck

NCT05929664 is registered in ClinicalTrials.gov with Thomas Jefferson University as lead sponsor.

NCT NCT05929664
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05929664 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Neoadjuvant REGN2810 (Cemiplimab) or REGN2810 (Cemiplimab) Plus REGN3767 (Fianlimab) in Cutaneous Basal Cell Carcinoma of the Head and Neck
Lead sponsor
Thomas Jefferson University
Phase
Phase 2
Overall status
Suspended
Start date
July 5, 2023
Completion date
July 5, 2031
Enrollment
70 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

basal cell carcinoma, locally advanced basal cell carcinoma